RU-39411

A synthetic steroidal antiandrogen

RU-39411 is a synthetic steroidal antiandrogen that was developed in the 1980s. It is a derivative of progesterone and is known for its ability to block the effects of androgens such as testosterone and dihydrotestosterone (DHT) in the body. RU-39411 has been studied for its potential use in the treatment of conditions like prostate cancer, androgenic alopecia, and hirsutism.

Mechanism of Action

RU-39411 functions as an antiandrogen by binding to the androgen receptor (AR) and preventing the activation of the receptor by endogenous androgens. This inhibition of androgen receptor activation leads to a decrease in the transcription of androgen-responsive genes, which in turn reduces the growth and proliferation of androgen-dependent tissues.

Pharmacokinetics

The pharmacokinetics of RU-39411 have been studied in various animal models. It is known to have a high affinity for the androgen receptor, and its effects are dose-dependent. The compound is metabolized in the liver and excreted primarily through the urine.

Clinical Applications

Although RU-39411 showed promise in preclinical studies, it has not been widely adopted in clinical practice. Research has focused on its potential use in:

• Prostate Cancer: By blocking androgen receptors, RU-39411 may inhibit the growth of prostate cancer cells, which often rely on androgens for proliferation.
• Androgenic Alopecia: The compound may reduce hair loss by preventing the miniaturization of hair follicles caused by DHT.
• Hirsutism: RU-39411 could potentially reduce excessive hair growth in women by blocking androgen effects.

Research and Development

RU-39411 remains primarily a research compound, with ongoing studies exploring its efficacy and safety profile. Its development has been overshadowed by other antiandrogens that have reached the market, such as flutamide and bicalutamide.

Also see

• Androgen receptor antagonist
• Steroidal antiandrogen
• Prostate cancer treatment
• Androgenic alopecia
• Hirsutism